Bis(bipyridine)ruthenium(II) Ferrocenyl β‐Diketonate Complexes: Exhibiting Nanomolar Potency against Human Cancer Cell Lines
作者:Matthew Allison、Pablo Caramés‐Méndez、Christopher M. Pask、Roger M. Phillips、Rianne M. Lord、Patrick C. McGowan
DOI:10.1002/chem.202004024
日期:2021.2.19
The synthesis and characterization of new bis(bipyridine)ruthenium(II) ferrocenyl β‐diketonate complexes, [(bpy)2Ru(Fc‐acac)][PF6] (bpy=2,2′‐bipyridine; Fc‐acac=functionalized ferrocenyl β‐diketonate ligand) are reported. Alongside clinical platinum drugs, these bimetallic ruthenium‐iron complexes have been screened for their cytotoxicity against MIA PaCa‐2 (human pancreatic carcinoma), HCT116 p53+/+
新的双(联吡啶)钌(II)二茂铁基β-二酮酸酯配合物[(bpy)2 Ru(Fc-acac)] [PF 6 ](bpy = 2,2'-联吡啶; Fc-acac =功能化的二茂铁基β-二酮酸酯配体)。除临床铂药物外,还对这些双金属钌铁配合物针对MIA PaCa-2(人类胰腺癌),HCT116 p53 + / +(人类结肠癌,p53)的细胞毒性进行了筛选。野生型)和ARPE-19(人类视网膜色素上皮)细胞系。除一种复合物外,该文库对癌细胞系具有纳摩尔效价,其相对效价分别比顺铂,卡铂和奥沙利铂高40倍,400倍和72倍。在低氧条件下,复合物仍具有细胞毒性(亚微摩尔范围),突出了其靶向低氧肿瘤区域的潜力。彗星试验用于确定其破坏DNA的能力,结果显示剂量依赖性破坏与细胞毒性结果密切相关。已经确定了它们治疗细菌和真菌菌株的潜力,并且突出了复合物对金黄色葡萄球菌和金黄色葡萄球菌的选择性生长抑制高达87–100%。白色念珠菌。